Akeso (HKSE:09926) Days Inventory : 1,106.00 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Akeso Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). Akeso's Average Total Inventories for the six months ended in Dec. 2023 was HK$372 Mil. Akeso's Cost of Goods Sold for the six months ended in Dec. 2023 was HK$61 Mil. Hence, Akeso's Days Inventory for the six months ended in Dec. 2023 was 1,106.00.

The historical rank and industry rank for Akeso's Days Inventory or its related term are showing as below:

HKSE:09926' s Days Inventory Range Over the Past 10 Years
Min: 939.18 Med: 1080.88 Max: 1494.02
Current: 939.18

During the past 6 years, Akeso's highest Days Inventory was 1494.02. The lowest was 939.18. And the median was 1080.88.

HKSE:09926's Days Inventory is ranked worse than
89.59% of 653 companies
in the Biotechnology industry
Industry Median: 190.92 vs HKSE:09926: 939.18

Akeso's Days Inventory increased from Dec. 2022 (909.67) to Dec. 2023 (1,106.00). It might indicate that Akeso's sales slowed down.

Inventory Turnover measures how fast the company turns over its inventory within a year. Akeso's Inventory Turnover for the six months ended in Dec. 2023 was 0.17.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Akeso's Inventory-to-Revenue for the six months ended in Dec. 2023 was 0.40.

Akeso Days Inventory Historical Data

The historical data trend for Akeso's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akeso Days Inventory Chart

Akeso Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Inventory

Get a 7-Day Free Trial

1,494.02

1,080.88

1,014.71

Akeso Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Days Inventory	Get a 7-Day Free Trial						910.92	1,644.62	909.67	752.78	1,106.00

Competitive Comparison of Akeso's Days Inventory

For the Biotechnology subindustry, Akeso's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akeso's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akeso's Days Inventory distribution charts can be found below:

* The bar in red indicates where Akeso's Days Inventory falls into.

Akeso Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Akeso's Days Inventory for the fiscal year that ended in Dec. 2023 is calculated as

	Days Inventory (A: Dec. 2023 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (381.729	+	428.617)	/	2 )	/	145.744	*	365
=	405.173					/	145.744	*	365
=	1,014.71

Akeso's Days Inventory for the quarter that ended in Dec. 2023 is calculated as:

	Days Inventory (Q: Dec. 2023 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (Q: Jun. 2023 )	+	Total Inventories (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (314.691	+	428.617)	/	2 )	/	61.326	*	365 / 2
=	371.654					/	61.326	*	365 / 2
=	1,106.00

Akeso (HKSE:09926) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Akeso's Inventory Turnover for the six months ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	61.326	/	371.654
	=	0.17

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Akeso's Inventory to Revenue for the six months ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	371.654	/	929.049
	=	0.40

Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.

Akeso Days Inventory Related Terms

Thank you for viewing the detailed overview of Akeso's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Akeso (HKSE:09926) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akeso Inc (HKSE:09926) » Definitions » Days Inventory

Comparable Companies

Traded in Other Exchanges

AKESF:USA 4RY:Germany

Address

6 Shennong Road, Torch Development Zone, Guangdong Province, Zhongshan, CHN, 528437

Website

https://www.akesobio.com

Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in Mainland China.

Akeso (HKSE:09926) Headlines

No Headlines